New York Blood Center’s Project ACHIEVE and Columbia University’s Columbia Research Unit are working in partnership for the New York City effort to advance the use of messenger ribonucleic acid (mRNA) technology in an HIV preventive vaccine study – HVTN 302.
FG Trade via iStock
After the past year of pandemic looniness, the COVID-19 vaccines are finally bringing a measure of hope. For some, questions on their safety remain, despite evidence otherwise. And, for people with HIV, there are questions about interactions with HIV meds. And, of course, with all the documented short-term side effects fever, nausea, fatigue, muscle and joint ache is it worth it?
These questions have been going through my mind, especially in the past weeks and months as the vaccines have been rolling out throughout the country. Vaccine trials to combat coronavirus were first announced in March 2020, very soon after the virus started to take hold in the U.S. and much of the country was put on lockdown. For me, this was incredibly soon and seemed rather reckless.